You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

For which of my patients with COPD is TRELEGY Ellipta most appropriate?

Go to Close Top

Sylvia

How is COPD impacting her life?

Due to Sylvia's worsening symptoms, she is starting to miss out on social events with friends. She has difficulty walking to the shops and struggles to keep her small garden tidy. She finds she can't keep up when playing with her young grandchildren.

Sylvia is not alone. In a database study of over 63,000 patients on COPD maintenance treatment:* 1, 2

  • 43% of patients had exacerbations in the last 12 months** 1, 2

In the same study, of over 43,000 patients with data available:

  • 52% of patients still experienced ongoing breathlessness 1, 2

What impact do exacerbations have on Sylvia's life?

Sylvia has begun to miss out on some of the things she enjoys most in life due to her worsening of symptoms, and these symptoms are putting her at greater risk of exacerbation. How can we help to break this cycle and help her to breathe better from today?

Sylvia life

Could TRELEGY Ellipta help reduce your patients’ COPD exacerbations?

Explore efficacy data
 

The patient need for a simple treatment routine

Complicated treatment routines may lead to missed doses, reduced adherence and worse treatment outcomes. 9-11 Complicated routines could be caused by the need for patients to use different inhalers, or to take multiple daily doses from the same inhaler. 1112

  • Using different inhalers requires patients to learn different inhalation techniques of varying complexities, which may lead to mishandling or inhalation errors 11, 12
  • Multiple daily dosing from the same inhaler could make it less likely that a patient will be adherent to their treatment routine 12
Treatment routine

How could the dosing schedule for TRELEGY Ellipta make a difference to your patients?

Discover more
 

*Patients aged ≥40, receiving one of the following: LAMA, LABA, LAMA/LABA or ICS/LABA 1
**Defined as ≥2 exacerbations without hospitalisation, ≥1 hospitalisations for COPD, or both 1
†A real-world clinical practice study of 55,076 patients with COPD in the United States between 1998 and 2006. Adherence was measured using PDC over 12 months following treatment initiation 10

ICS, inhaled corticosteroid; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic antagonist; OD, once daily; PDC, proportion of days covered

References:

  1. Rebordosa C et al. Pharmacoepidemiol Drug, Saf 2019; 28:126–133.
  2. Rebordosa C et al. Pharmacoepidemiol Drug, Saf 2019; 28:126–133 (supplementary information).
  3. Barnes PJ et al. Nat Rev Dis Primers 2015; doi: 10.1038/nrdp.2015.76.
  4. Donaldson G et al. Thorax 2002; 57:847–852
  5. Seemungal TA et al. Respir Med 1998; 157:1418–1422.
  6. Halpin DMG et al. Respir Med 2017; 128:85–91.
  7. Andersson F et al. Respir Med 2002; 96:700–708.
  8. Punekar YS et al. Pulm Ther 2016; 2:59–72.
  9. Bourbeau J et al. Thorax 2008; 63:831–838.
  10. Toy EL et al. Respir Med 2011; 105:435–441.
  11. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease (GOLD), 2018. Available at https://goldcopd.org/gold-reports/ (Accessed September 2019).
  12. Melani AS et al. Respir Med 2011; 105:930–938.
  13. TRELEGY Ellipta SmPC, 2019.


TRELEGY Ellipta was created in collaboration with

Innoviva

Adverse events should be reported to the Health Products Regulatory Authority (HPRA) using an Adverse Reaction Report Form obtained either from the HPRA or electronically via the website at www.hpra.ie. Adverse reactions can also be reported to the HPRA by calling: (01) 6764971. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.

© 2019 GlaxoSmithKline group of companies or its licensor

TRELEGY Ellipta OD is indicated for maintenance treatment in adult patients with moderate-to-severe COPD who are not adequately treated by a combination of an ICS and a LABA, or a combination of a LAMA and a LABA 13